Meridian Bioscience, Inc. (NASDAQ:VIVO) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience, Inc. (NASDAQ:VIVO) stock performance was 0.37% in last session and finished the day at $21.45. Traded volume was 155,365 million shares in the last session and the average volume of the stock remained 255.89 million shares. The beta of the stock remained 1.12. Meridian Bioscience, Inc. (NASDAQ:VIVO) insider ownership is 2.00%.

The Vermillion Inc. (NASDAQ:VRML) board of directors’ compensation committee has approved 2013 cash bonuses for Thomas McLain, president and CEO, and other C-level executives of the Austin life sciences company. Vermillion, Inc. (NASDAQ:VRML) dropped -4.51 percent to $2.75 yesterday on volume of 57,156.00 million shares. The intra-day range of the stock was $2.75 to $2.82. Vermillion, Inc. (NASDAQ:VRML) has a market capitalization of $98.52 million.

Atossa Genetics Inc (NASDAQ:ATOS) Stock was panned all round at the markets during trading on 4thMarch, which led to the market valuation of the diagnostic substance and medical equipment manufacturer taking a 11.3 percent hit during the day’s trading. Atossa Genetics Inc (NASDAQ:ATOS)’s stock on Mar14, 2014 closing price of $1.77. Its fifty two weeks range is $1.72 -$12.40. The total market capitalization recorded $31.90 million. The overall volume in the last trading session was 115,352 million shares. In its share capital, Atossa Genetics Inc (NASDAQ:ATOS) has 15.83 million outstanding shares.

Equities researchers at Piper Jaffray assumed coverage on shares of IDEXX Laboratories (NASDAQ:IDXX) in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $125.00 price target on the stock. On Friday, shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) advanced 1.44% to close the day at $127.91. Company return on investment (ROI) is -98.10% and its monthly performance is recorded as -25.00%. IDEXX Laboratories, Inc. (NASDAQ:IDXX) quarterly revenue growth is -37.01%.